Pfizer Recalls Norpace CR Capsules for Failed Dissolution Specification
Pfizer is recalling Norpace CR (disopyramide phosphate) capsules because they failed to meet dissolution specifications. The recall covers specific lots distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class III, which indicates a low risk of adverse health consequences. The issue is a quality control failure (dissolution specification) rather than a direct safety hazard like contamination or mislabeling of a common allergen.
Plain-English summary
Pfizer Inc. is recalling Norpace CR (disopyramide phosphate) extended-release capsules, 150 mg, due to a failure to meet dissolution specifications. The affected product is packaged in 100-count bottles (NDC 0025-2742-31) and 500-count bottles (NDC 0025-2742-51). The recall includes 4,005 bottles of the 100-count size and 104 bottles of the 500-count size.
The affected lots are C150065 and C150064, with an expiration date of 6/16. The product was distributed nationwide. Norpace CR is a prescription-only medication used for the treatment of certain heart rhythm disorders.
Consumers and healthcare providers should check their inventory for the specific lot numbers and NDC codes listed above. If the product matches the recalled description, it should be returned to the pharmacy or distributor for a refund or replacement. Patients should consult their healthcare provider for alternative treatment options if necessary.
The recalled product
- Product
- NORPACE CR (DISOPYRAMIDE PHOSPHATE)
- Brand
- NORPACE CR
- Manufacturer
- Pfizer Inc.
- Category
- Drug — Prescription Drug
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot #: C150065
- C150064
- Exp 6/16
UPCs (4)
- 0300252752314
- 0300252762313
- 0300252742315
- 0300252732316
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · NORPACE CR
- LowPfizer Recalls Norpace CR Capsules for Failed Dissolution Specification
FDA (Drugs) · 2013-06-26
Same manufacturer · Pfizer Inc.
See all →- HighSodium bicarbonate injection vials recalled for lack of assurance of sterility
FDA (Drugs) · 2025-08-27
- HighEpinephrine injection vials recalled for lack of assurance of sterility
FDA (Drugs) · 2025-08-27
- HighBicillin L-A 2.4 million unit vials recalled after particulates found
FDA (Drugs) · 2025-08-06
- HighBicillin L-A penicillin vials recalled after particulates found during visual inspection
FDA (Drugs) · 2025-08-06
- ModerateDobutamine Injection Recall Due to Discoloration and Cracked Vials
FDA (Drugs) · 2025-07-02
Same hazard · quality control
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateDuoGlide Short-Term Dialysis Catheter recall due to deficient manufacturing
FDA (Devices) · 2026-07-08
- ModeratedirectCHECK whole blood control labeled with incorrect performance range
FDA (Devices) · 2026-06-24
- HighAmyloid plasma controls recalled over falsely elevated ratio results
FDA (Devices) · 2026-02-11
- HighpTau 217 plasma controls recalled over falsely elevated ratio results
FDA (Devices) · 2026-02-11